Virus vaccine hopes raised by fresh trials | The Business Standard
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
The Business Standard

Sunday
October 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
    • GOVT. Ad
  • More
    • Subscribe
    • Videos
    • TBS Graduates
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Long Read
    • Interviews
    • Offbeat
    • Tech
    • Magazine
  • বাংলা
SUNDAY, OCTOBER 01, 2023
Virus vaccine hopes raised by fresh trials

Coronavirus chronicle

BSS/AFP
17 July, 2020, 09:25 am
Last modified: 17 July, 2020, 09:32 am

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • The next big advance in cancer treatment could be a vaccine
  • MoU signed with US company to set up first ever vaccine producing plant in country
  • Positive results for potential first chikungunya vaccine
  • G7 plans new vaccine effort for developing nations, Yomiuri reports

Virus vaccine hopes raised by fresh trials

Results of the trial are expected to be published in The Lancet medical journal next week, Oxford said in a statement

BSS/AFP
17 July, 2020, 09:25 am
Last modified: 17 July, 2020, 09:32 am
File Photo: Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo
File Photo: Small bottles labelled with a "Vaccine Covid-19" sticker and a medical syringe are seen in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration/File Photo

Hopes of an effective COVID-19 vaccine being developed in the near future have been raised after two separate studies showed potential positive results, British media reported Thursday.

A University of Oxford trial showed its prototype vaccine generated an immune response against the virus, the reports said.

Blood samples taken from a group of some 1,000 volunteers who were given the vaccine stimulated antibodies and "killer T-cells", according to the Daily Telegraph newspaper.

Previous research has shown that T-cells can remain in the body for years and help fight viruses.

Results of the trial are expected to be published in The Lancet medical journal next week, Oxford said in a statement.

The potential development comes after US biotech firm Moderna said on Tuesday it would start the final stage of human trials for its vaccine candidate on July 27.

It said it had had promising results from earlier testing. Up to 30,000 Americans are expected to take part in the trials.

Moderna is considered to be in a leading position in the global race for a vaccine. Its study is set to run until October 2022 but preliminary results should be available before then.

The top US infectious diseases official, Anthony Fauci, has called the Moderna results "really quite good news".

The studies are the latest to inspire hopes of developing a vaccine after nearly 600,000 deaths and 13.4 millions cases worldwide since the outbreak began in China last year.

Meanwhile, a third group, BioNTech, a German company in partnership with US pharma giant Pfizer, plans to carry out its own trials on a vaccine involving 30,00 people.

Top News

Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Containers piled up at Chattogram port. File Photo: TBS
    Exports fetch $4.31 billion in September, lowest since April
  • No source tax can be deducted from IT freelancing sector: Cenbank
    No source tax can be deducted from IT freelancing sector: Cenbank
  • Remittance earnings in September lowest in 41 months
    Remittance earnings in September lowest in 41 months

MOST VIEWED

  • Photo: TBS
    Habibur Rahman takes charge as 36th DMP commissioner
  • Paperfly aborts flight
    Paperfly aborts flight
  • Photo: Collected
    The top 3 smartwatches of 2023: A glimpse into the future
  • Photo: TBS
    Dhaka traffic slowest in world: Study
  • Harsher bilateral loans set to make external debt repayment tougher
    Harsher bilateral loans set to make external debt repayment tougher
  • Illustration: TBS
    Shokh and Sarika’s quest of return

Related News

  • Moderna ties up with Immatics to boost cancer vaccine development
  • The next big advance in cancer treatment could be a vaccine
  • MoU signed with US company to set up first ever vaccine producing plant in country
  • Positive results for potential first chikungunya vaccine
  • G7 plans new vaccine effort for developing nations, Yomiuri reports

Features

Illustration: Collected

Apology to a life forgotten to live

2h | Features
Photo: Kazi Ashraf Uddin

Coffee: More than a beverage, something of a beloved

5h | Features
The price back to the normal range is possible if the corporations who control the feed market reduce the feed and chick prices. Photo: Noor-A-Alam

Will eggs ever return to their 'normal' price?

8h | Features
Photo & Coffee Sketch: Touseful Isalm

A coffee conversation with Rumi

1d | Features

More Videos from TBS

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

Everything about the ICC Cricket World Cup 2023 stadiums: Part 1

11m | TBS SPORTS
Apple is bringing new software updates to prevent overheating

Apple is bringing new software updates to prevent overheating

2h | Tech Talk
A unique study cafe in the city

A unique study cafe in the city

1h | TBS Stories
Reserves are falling even as the dollar's share of global payments rises

Reserves are falling even as the dollar's share of global payments rises

4h | TBS Economy
EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]